With formoline Interval 5:2, Certmedica introduces a user-centered treatment unit for weight management. The combination of the medical devices formoline L112 and formoline mannan supports the implementation of 5:2 intermittent fasting, improves everyday usability, and promotes adherence and long-term compliance through a clear structure and evidence-based principles.
Mit formoline Intervall 5:2 führt Certmedica eine anwenderzentrierte Behandlungseinheit für das Gewichtsmanagement ein. Die Kombipackung aus dem Medizinprodukt formoline L112 und formoline mannan unterstützt gezielt die Umsetzung des 5:2-Intervallfastens, verbessert die Alltagstauglichkeit und fördert Adhärenz sowie langfristige Compliance durch klare Struktur und evidenzbasierte Wirkprinzipien.
Abstract
Metabolic syndrome (MS) is one of the major risk factors for the development of diabetes mellitus type 2 and cardiovascular disease. Polyglucosamine L112 (formoline L112) is a high-effective-weight fat binder whose efficacy in weight reduction has been demonstrated in a randomized, double-blind, placebo-controlled study (POSO II, 2023) (4). A recent subgroup analysis (2025) investigate
Abstract
Metabolic syndrome (MS) is one of the major risk factors for the development of diabetes mellitus type 2 and cardiovascular disease. Polyglucosamine L112 (formoline L112) is a high-effective-weight fat binder whose efficacy in weight reduction has been demonstrated in a randomized, double-blind, placebo-controlled study (POSO II, 2023) (4). A recent subgroup analysis (2025) investigate
Certmedica International hat die COFEPRIS-Zulassung für die formoline L112-Serie in Mexiko erhalten. Die Produkte (500 mg und 750 mg) sind Medizinprodukte der Klasse III zur Behandlung von Übergewicht und Adipositas. Angesichts hoher Adipositasraten bieten sie eine sichere Option zur Gewichtsreduktion und werden bis Mitte 2025 in über 6.000 Apotheken und Kliniken eingeführt.
Manfred Stoll (1), Norman Bitterlich (2) and Umberto Cornelli (3)
1 Diabetological Center, Frankfurter Str. 50, D-63303 Dreieich, Germany.
2 Medizin and Service GmbH, Abt. Biostatistik, Boettcherstr. 10, D-09117 Chemnitz, Germany.
3 Loyola University School of Medicine, 2160 South First Avenue, Maywood, Illinois 60153, USA.
Received: 8 May 2016, Accepted: 8 November 2016, Published onl
Janina Willers (1*), Stefanie C. Plötz (1) and Andreas Hahn (1)
1 Institute of Food Science, Leibniz University Hannover, Hannover, Germany
Received 8th February 2012, Accepted 12th May 2012, Online Ready 21st May 2012, European Journal of Food Research & Review, 2(1): 29-45, 2012
Abstract
Aims: To examine the efficacy of a weight loss strategy using a high-protein formula diet in